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TO THE EDITOR
Rodent models with autoimmune dis-
eases provide many insights to unravel
the complexities of human diseases as
tools for hypothesis testing and pre-
clinical drug efficacy screening (Sun
et al., 2008). Nearly 10 years ago, we
performed a comparative mouse and
human gene array study to identify
potentially dysregulated genes in alo-
pecia areata (AA). One such gene was
Clta4, a co-stimulatory T-cell ligand
that binds B7.1 (CD80) and B7.2
(CD86) on antigen-presenting cells
(APCs) (Carroll et al., 2002). As AA is
an autoimmune disease in humans and
mice, we hypothesized that CTLA4,
through its co-stimulatory T cell and
APC pathways, is a critical regulator of
AA onset and maintenance, based on
studies in the mouse model of AA
(Sundberg et al., 1994). We performed
preclinical studies by intraperitoneally
injecting mAbs against APC surface
markers B7.1 (CD80) and B7.2 (CD86),
and a monoclonal anti-CTLA4 antibody
into C3H/HeJ mice with and without
AA to disrupt T cell and APC inter-
actions involving CTLA4. The studies
conclusively showed that these mAbs
effectively prevented onset of AA in the
mouse model (Carroll et al., 2002; Sun
et al., 2008). Subsequently, we confirmed
increased numbers of skin-infiltrating
cells and skin-draining lymph node
cells in AA mice expressed CD80/86,
whereas CTLA4 was increased in both
populations; primarily on CD4þ /CD25
cells (Zoller et al., 2002). CTLA4 (CD152)
was similarly found with significantly
elevated expression in peripheral blood
CD4þ /CD25 cells of AA patients
(Zoller et al., 2004a), and a significantly
larger percentage of peripheral blood
mononuclear cells expressed CD80
(Zoller et al., 2004b).
Recently, two landmark papers were
published, the first a human genome-
wide association study (Petukhova et al.,
2010), and more recently, another that
replicated CTLA4 as a major candidate
gene for AA susceptibility in humans
(John et al., 2011), providing exciting
data on human AA and validating
the first bona fide susceptibility locus
outside the HLA. The co-stimulatory
locus containing the CTLA4 gene on
mouse chromosome 1 (human chromo-
some 2) was not previously identi-
fied as a quantitative trait locus in the
mouse AA model (Sundberg et al., 2003,
2004). However, the convergence of
expression data from the AA model
with the human studies confirm our
hypothesis that antigen presentation
in association with CTLA4–CD80/86
co-stimulation is implicated in the
development of AA and provides a
crucial foundation for future human
clinical studies. For example, the pre-
clinical data from the mouse AA
model could be used to support testing
of Abatacept (Orencia, Bristol-Myers
Squibb, Corporate Headquarters, New
York, NY), a drug approved by the
United States Food and Drug Adminis-
tration to treat autoimmune rheumatoid
arthritis (Moreland et al., 2006), as a
safe and effective therapy for human
AA. Abatacept is a fusion protein with
the extracellular domain of CTLA4 fused
with the hinge CH2 and CH3 domains
of human IgG1. It is a selective modu-
lator that binds to the co-stimulatory
protein CD28 on T cells and B7 proteins
(CD80/CD86) on APCs. As a possible
alternative, Ipilimumab (Yervoy, Bristol-
Myers Squibb) is a fully humanized anti-
CTLA4 mAb, United States Food and
Drug Administration approved to treat
metastatic melanoma; however, Ipilimu-
mab has been documented to induce
human autoimmune diseases in clini-
cal use (Callahan et al., 2010), whereas
Abatacept has not so been documented
so far. Abatacept is associated with an
increased incidence of infections because
of its immunosuppressive effects (Dubois
and Cohen, 2009), but this may be
acceptable to AA patients if it is shown
to be efficacious for hair growth.
Why is there a delay in a detailed
exploration of the CTLA4 pathway(s) in
human AA? A lingering bias against
animal models of human disease is
widespread in the medical and lay
community, partly based on the not
uncommon lack of treatment efficacy
confirmation and/or safety issues re-
vealed in subsequent human clinical
trials. The explosion of genetic analyses
studies shows that at a cellular and
genetic level, there are many common
regulatory pathways in human diseases
and their respective animal models.
When findings in a putative animal
model for a specific human disease
does not fulfill all the precise features of
the human disease it most likely means
that: (1) the original model selection
was flawed, or the human disease is
incompletely or incorrectly character-
ized, (2) the human disease is hetero-
genic due to genetic, ethnic, age, and
gender differences in the disease sus-
ceptibility and/or variations in environ-
mental influence; issues that cannot
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always be replicated with inbred ani-
mal models in a regulated environment,
or (3) the methodology in the model
studies or subsequent human trials was
flawed leading to systematic bias (van
der Worp et al., 2010). The challenge in
developing any new therapy for human
diseases involves the careful selection
of a suitable preclinical model(s) to be
used and well-defined human subjects
to be evaluated. Although such issues
cannot be ignored, the identification of
a relevant animal model for a human
disease can prove invaluable for study-
ing disease mechanisms and for devel-
oping and screening new treatments.
The discoveries made in humans,
rats, and mice with AA over the past 20
years led to the understanding just how
complex its genetics, molecular mechan-
isms, and its molecular pathways are
(Carroll et al., 2002; Subramanya et al.,
2010) in regulating its susceptibility,
progression, and resolution (Sundberg
et al., 2003, 2004; Petukhova et al.,
2010; John et al., 2011). Autoimmunity
in humans and other mammals have
many biological and genetic features
that share many common regulatory
pathways and provide valid insights
(Sundberg and Schofield, 2009). Though
the AA models are not perfect represen-
tations of human AA, the fundamental
concepts of AA in rodents and humans
have proven remarkably similar thus so
far. By integrating findings from multiple
sources, great advances will continue to
assist in developing safe and effective
treatments for human and animal dis-
eases including AA.
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TO THE EDITOR
Thymic stromal lymphopoietin (TSLP)
is a key keratinocyte (KC)-derived
cytokine involved in the pathogenesis
of atopic diseases, including atopic
dermatitis (AD) (Liu et al., 2007; Ziegler
and Artis, 2010). Its expression was
found to be increased in skin KCs from
AD patients (Soumelis et al., 2002). We
(Li et al., 2005), and others (Yoo et al.,
2005) have shown that transgenic mice
overexpressing TSLP in KCs develop an
AD-like syndrome, indicating that TSLP
expression is sufficient to initiate
AD-like inflammatory responses. MoreAbbreviations: AD, atopic dermatitis; CT, control; TSLP, thymic stromal lymphopoietin
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